The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Strong and distinct cytoplamic/membraneous reaction in a varying fraction of all carcinoma types. No positivity in melanomas, gliomas, lymphomas or clear cell carcinoma of the kidney.
Most malignancies showed moderate to strong cytoplasmic/membranous positivity. Malignant gliomas, lymphomas, testis renal and liver cancers were generally negative.
Moderate to strong membranous staining, often accompanied with cytoplasmic positivity, was observed in most adenocarcinomas and squamous cell carcinomas. Strongest staining was found in urothelial cancers, while malignant gliomas, lymphomas and melanomas were negative.
Validation
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for at least one of the genes whereas any of the other genes has no available gene/protein characterization data or is contradicted by gene/protein
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for at least one of the genes whereas any of the other genes has no available gene/protein characterization data or is contradicted by gene/protein
One antibody yielding a staining pattern which is consistent with gene/protein characterization data
